Human papilloma virus vaccine - More than a vaccine

Current Opinion in Obstetrics and Gynecology

Volumn 19, Issue 6, 2007, Pages 541-546

  Pallecaros, Anna ^a,c   Vonau, Barbara ^b  

^a The Princess Grace Hospital   (United Kingdom)

^b Bromley Hospitals NHS Trust   (United Kingdom)

^c Princess Grace Hospital   (United Kingdom)

Author keywords

Cervical cancer; Genital warts; Prophylactic human papilloma virus vaccines

Indexed keywords

WART VIRUS VACCINE;

CONDYLOMA; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; HEALTH CARE PERSONNEL; HEALTH SURVEY; HUMAN; INCIDENCE; MATHEMATICAL MODEL; MEDICAL EDUCATION; MEDICAL ETHICS; PATIENT INFORMATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEMANTICS; SOCIAL PSYCHOLOGY; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

CHILD; COST-BENEFIT ANALYSIS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT EDUCATION AS TOPIC; POPULATION SURVEILLANCE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 36248969146     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3282f1a91b     Document Type: Review

References (49)

1. Bosch FX, Iftner F. Aetiology of cervical cancer. NHSCSP publication no 22. London: NHS Cancer Screening Programmes; 2005.
2. Bosch FX, de Sanjose S. Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31:3-13.
3. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus like particle vaccine through 5 years of follow up. Br J Cancer 2006; 95:1459-1466.
4. Joint Committee on Vaccination and Immunisation, UK. Minutes of the HPV Sub-group meeting, Wednesday 28 February 2007. www.advisorybodies. doh.gov.uk/jcvi/minutes.htm; 2007. These minutes illustrate how an expert committee works to develop recommendations for HPV vaccination strategies at a national level.
5. Kohli M, Ferko N, Martin A, et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 2007; 96:143-150. This paper shows how a mathematical model can be used to predict the impact of vaccination within the existing screening programme of the UK. It outlines the ways in which such a model can extrapolate beyond the results of clinical trials and explore the long-term public health benefits of vaccination.
6. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006; 28:88-100. This is an excellent presentation of how a mathematical model can assess alternative vaccination strategies, within an organized cancer screening programme, in this case in the USA. How differing vaccination strategies can powerfully affect epidemiological outcomes and cost-effectiveness are clearly and comprehensively set out.
7. Van de Velde N, Brisson M, Boily MC. Modelling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007; 165:762-775. This paper outlines how natural immunity and the duration of vaccine protection are key parameters in models of vaccine effectiveness and, thus, why their understanding and measurement should be priorities for future research.
8. French KM, Barnabas RV, Lehtinen M, et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimumage- and sex-specific pattern of vaccination in Finland. Br J Cancer 2007; 96:514-518. This is a comprehensive exploration of how differing vaccination strategies can affect outcomes of a national vaccination programme in Finland.
9. Burchell AN, Richardson H, Mahmud SM, et al. Modelling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol 2006; 163:534-543. This paper models the high transmissibility of HPV, underlining the need for an effective vaccine, notwithstanding a potential protective effect from condom use.
10. Tucker ME. Cervical ca vaccine highly effective at 5.5 years. Internal Med News 2007; 40:1 April 2007, page 9.
11. Lacey JN, Lowndes C, Shah K. Burden and management of noncancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24 (suppl 3):S35-S41. This is an excellent and comprehensive review of current knowledge about the causative agents of ano-genital warts. It ties together epidemiological, investigative, clinical and financial data.
12. Dunne EF, Nielson CM, Stone KM, et al. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006; 194:1044-1057. This paper reviews recent literature about HPV prevalence in heterosexual men, highlighting the need for more studies of natural history and transmission.
13. Anon. Leading edge: who should be vaccinated against human papillomavirus? Lancet Infect Dis 2006; 6-1. DOI:10.1016/S1473-3099(05)70301-7.
14. Constantine N, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolescent Health 2007; 40:108-115. This is an in-depth evaluation of parental attitudes to HPV vaccination.
15. Woodhall S, Lehtinen M, Verho T, et al. Anticipated acceptance of HPV vaccination at the baseline of implementation: a survey of parental and adolescent knowledge and attitudes in Finland. J Adolescent Health 2007; 40:466-469. This paper outlines how both parents and adolescents view the HPV vaccine at the outset of a national screening programme.
16. Marshall H, Ryan P, Robertson D, Baghurst P. A cross-sectional survey to assess community attitudes to introduction of human papillomavirus vaccine. Perspect Sexual Reprod Health 2007; 39:121-122. This large survey, based on telephone interviews, investigates adult attitudes to HPV vaccination across both rural and urban communities in South Australia.
17. Bair RM, Mays RM, Sturm LA, Zimet GD. Acceptability of human papillomavirus vaccine among Latina mothers. J Adolescent Health 2007; 40 (suppl):S16-S17. This is an important study of parental attitudes to vaccination in a nonwestern setting.
18. Kemp C. Factors associated with parental acceptance of HPV vaccines. AAP News 2006; 27:2-12. This paper explores the impact of giving written information about the HPV vaccination to parents.
19. Dinh TA, Rosenthal SL, Doan ED, et al. Attitudes of mothers in Da Nang, Vietnam toward a human papillomavirus vaccine. J Adolescent Health 2007; 40:559-563. This article makes an important contribution to our knowledge of attitudes to vaccination in nonwestern settings.
20. Kahn J. Maximizing the potential public health impact of HPV vaccines: a focus on parents. J Adolescent Health 2007; 40:101-103. This paper ties together the barriers to vaccination which need to be overcome if HPV vaccination strategies are to fulfill their public health potential.
21. Crosby R, Schoenberg N, Hopenhayn C. Correlates of intent to be vaccinated against HPV: an exploratory study of college aged women. J Adolescent Health 2007; 40:S47. This paper demonstrates individual characteristics that are important to understanding voluntary acceptance of an HPV vaccine in women.
22. Skinner SR, Kang M, Rosenthal SL. Vaccinating young adults against human papillomavirus: the importance of understanding health decision-making and behaviour. Sexual Health 2007; 4:129-132. This paper ties together data about young people's attitudes to HPV vaccination in Australia, in order to help inform provider strategies.
23. Zimet GD, Liddon N, Rosenthal SL, et al. Chapter 24: psychosocial aspects of vaccine acceptability. Vaccine 2006; 24 (suppl 3):S201-S209. A comprehensive and in-depth analysis of psychosocial issues relating to HPV vaccination, both before and after vaccination. This review highlights areas that need further research in both resource-rich and resource-poor settings.
24. Zimet GD. Understanding and overcoming barriers to human papillomavirus vaccine acceptance. Curr Opin Obstet Gynaecol 2006; 18 (suppl 1):S23-S28.
25. Crosby RA, Benitez J, Young A. Correlates of intent to be vaccinated against HPV: an exploratory study of college-aged males. The 135th Annual Meeting & Exposition of American Public Health Association; 3-7 November 2007; Washington DC: American Public Health Association. Abstract 160236.
26. Giles M, Garland S. A study of women's knowledge regarding human papillomavirus infection, cervical cancer and human papillomavirus vaccines. Aust N Z J Obstet Gynaecol 2006; 46:311-315. This questionnaire-based study demonstrates why patient and provider education about HPV is an important priority.
27. Dempsey AF, Zimet GD, Davis RL, et al. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics 2006; 117:1486-1493. This is a large cross-sectional survey demonstrating how written information can impact on parental knowledge and attitudes towards HPV vaccination.
28. Brabin L, Roberts S, Kitchener H. A semi-qualitative study of attitudes to vaccinating adolescents against human papillomavirus without parental consent. BMC Public Health 2007; 7:20.
29. Sherris J, Friedman A, Wittet S, et al. Chapter 25: education, training, and communication for HPV vaccines. Vaccine 2006; 24 (suppl 3):S210-S218. This is an incisive and comprehensive analysis of the health education challenges facing HPV vaccination strategies today.
30. Hunter J. Cervical cancer educational pamphlets: do they miss the mark for Mexican Immigrant women's needs? Cancer Control (Cancer, Culture and Literacy supplement) 2005. November, 42-50.
31. McCaffery K, Waller J, Forest S. Testing positive for human papilloma virus in routine cervical screening: examination of psychological impact. BJOG Int J Obstet Gynaecol 2004; 111:1437-1443.
32. Maissi E, Marteau T, Hankins M, et al. Psychological Impact of human papilloma testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. BMJ 2004; 328: 1-6.
33. Anon. Leading edge: lost in transmission. Lancet Oncol 2007; 8:181. This editorial explores the challenges faced by today's multimedia for successful patient education.
34. Rupp R, Rosenthal SL, Middleman AB. Vaccination: an opportunity to enhance early adolescent preventive services. J Adolescent Health 2006; 39:461-464. This paper draws together the health needs of adolescents and highlights the need for improved service provision to this sector.
35. Daley MF, Liddon N, Crane LA, et al. A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics 2006; 118:2280-2289. This is an important survey of provider concerns and attitudes towards recommending HPV vaccination to their patients.
36. Jijon V. Global HPV vaccination called by physicians. Medimix International News, 20 July. www.medimix.net/en/news/ global_HPV_vaccination_called_ for_by_physicians; 2007.
37. Gonik B, Jones T, Fasano N, et al. Vaccine-preventable diseases: improving the obstetrician/gynaecologist's knowledge and communication practice patterns. Am J Obstet Gynecol 2001; 185:S162.
38. Waller J, Marlow L, Wardle J. The Association between knowledge of HPV and feelings of stigma, shame and anxiety. J Sexually Transmitted Infection 2007; 83:155-159. This paper demonstrates how patient pretest education about HPV can reduce subsequent adverse psychological outcomes.
39. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus Infections with multiple types and risk of cervical dysplasia. Cancer Epidemiol Biomarkers Prev 2006; 15:1274-1280.
40. Adams M, Jasani B, Fiander A. Human papilloma virus (HPV) prophylactic vaccination:challenges for public health and implications for screening. Vaccine 2007; 25:3007-3011. This paper considers the diversity of factors that may interplay in individuals of differing ages and cultures who may be involved in HPV vaccination in the future. The effects on vaccine efficacy and cervical screening are considered.
41. Shaw D. Women's right to health and the Millennium Development Goals: promoting partnerships to improve access. Int J Gynecol Obstet 2006; 94:207-215. This overview of the committments of 189 member states of the United Nations to gender equality highlights the need to explicitly articulate the sexual health needs of women, especially through improved access.
42. Akers AY, Newmann SJ, Smith JS. Factors underlying disparities in cervical cancer incidence, screening, and treatment in the United States. Curr Problems Cancer 2007; 31:157-181. An incisive study of the healthcare disparities which limit otherwise highly effective preventive public health strategies.
43. Splete H. 'Tough choices' feared on HPV vaccine access. Pediatric News 2006; 40:19. This article highlights the increasing concern about funding disparities affecting access to the HPV vaccine.
44. Kane MA. Chapter 9. Delivering HPV vaccine in the industrial and developing world: the role of the ob-gyn community. Int J Gynecol Obstet 2006; 94 (suppl 1):S89-S94. A comprehensive review of the challenges facing current attempts to deliver the HPV vaccine to the developing world. The possible role of physicians worldwide is explored.
45. Katz IT, Wright AA. Preventing cervical cancer in the developing world. N Engl J Med 2006; 354:1110. This paper outlines key global disparities.
46. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries - key challenges and issues. N Engl J Med 2007; 356:1908-1910. This is an excellent and comprehensive review of healthcare disparities affecting the burden of HPV pathology in a global context. The authors explore challenges facing strategies to improve access to primary preventive tools.
47. Pollack AE, Balkin M, Edouard L, et al., WHO/UNFPA Working Group on Sexual and Reproductive Health and HPV Vaccines. Ensuring access to HPV vaccines through integrated services: a reproductive health perspective. Bull World Health Organ 2007; 85:57-63. A review of current strategies to improve access to preventive healthcare against HPV disease in resource poor settings.
48. Kamanger F, Dores G, Anderson W. Patterns of cancer incidence, mortality, and prevalence across five continents: defingin priorities to reduce cancer disparities in differnet geographic regions of the world. J Clin Oncol 2006; 24:2137-2150. This paper outlines how risk factors, behaviour and socio-cultural, economic and healthcare differences intertwine to produce the differing geographic patterns of cancer across the globe. They suggest how understanding these differences can help prioritize efforts to reduce global cancer disparities.
49. Parry J. Vaccinating against cervical cancer. Bull World Health Organ 2007; 85:89-90. This article suggests current optimism within the World Health Organization towards the potential impact of the HPV vaccine.